Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl

Bonomo, L; Raja, Aishwarya; Tan, Kathryn; Guttman‐Yassky, Emma

doi:10.1016/j.jdcr.2017.09.010

Cited by 17 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Given the activation of this IL-23/Th17 pathway with CARD14 mutations, a better therapeutic response to ustekinumab versus TNFα inhibition or broad immunosuppressants is not surprising. Furthermore, recognition that lesional skin in PRP shows activation of the IL-23/Th17 pathway, even without CARD14 mutation, [10][11][12][13][14] has led to successful intervention with ustekinumab 15,16 and the IL-17 pathway inhibitors secukinumab, 17,18 ixekizumab, 19 and brodalumab. 20…”

Section: Biopsy Samples Of Previously Reported Cases Have Shown Alter...mentioning

confidence: 99%

CARD14‐associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature

Frare

Blumstein

Paller

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

CARD14‐associated papulosquamous eruption (CAPE) is a proposed term that encompasses features ranging from psoriasis to pityriasis rubra pilaris (PRP) in association with CARD14 mutations. The early onset of the disease, prominent facial involvement, family history of an autosomal dominant trait, and poor response to conventional treatment are characteristics of CAPE that distinguish it from classical psoriasis and PRP. We describe the clinical features, family history, and response to therapy in three unrelated children with CAPE and compare these characteristics with those of previously described pediatric patients. Testing for CARD14 mutations in children with early onset of features of psoriasis or pityriasis rubra pilaris and resistance to conventional therapy should be considered.

show abstract

Section: Biopsy Samples Of Previously Reported Cases Have Shown Alter...mentioning

confidence: 99%

CARD14‐associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature

Frare

Blumstein

Paller

et al. 2021

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…As regards anti-IL-12/23 agents, ustekinumab was used in 18.8% of examined PRP cases, showing a high effectiveness (CR of 80.7%) with low relapse rates at the withdrawal. 8,[12][13][14][15] In most cases, it was employed as rescue treatment for recalcitrant forms (88.5%), but first-line use was also reported (11.5%). 8 In addition, ustekinumab was shown to be effective not only in sporadic PRP but also in familial forms and in patients unresponsive to anti-IL17A…”

Section: Discussionmentioning

confidence: 99%

“…Anti‐TNF‐α, anti‐IL12/23, anti‐IL23, and anti‐IL17A have been employed so far up to 138 PRP patients (Table 1). 4‐15 Concerning TNF‐α inhibitors, infliximab is the most employed (26.8% of all PRP cases), followed by etanercept (17.4%) and adalimumab (14.5%) reaching a complete response (CR) in 54.3% of cases (Table 1). 2,3,5 As regards anti‐IL23, guselkumab has been employed in the treatment of two refractory cases of adult PRP, reaching a CR as early as 12 weeks, without any relapse 6 .…”

Section: Discussionmentioning

confidence: 99%

“…Overall, they showed a CR of 68.7%. As regards anti‐IL‐12/23 agents, ustekinumab was used in 18.8% of examined PRP cases, showing a high effectiveness (CR of 80.7%) with low relapse rates at the withdrawal 8,12‐15 . In most cases, it was employed as rescue treatment for recalcitrant forms (88.5%), but first‐line use was also reported (11.5%) 8 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review

Camela

Miano

Caterino

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis characterized by hyperkeratotic follicular papules and erythematous-desquamative plaques that tend to progressively evolve into erythroderma. Treatment is challenging given that international guidelines are not available and large-scale trials do not exist. Traditionally, many topical and systemic drugs had been used as consolidated agents; recently, biologicals are gaining increasing importance, promisingly dominating the therapeutic scenario ahead. Herein, we present a case series showing the "past" and the "future" therapeutic approaches to erythrodermic PRP, one case treated with acitretin and nb-UVB phototherapy combination, while the other with ustekinumab, performing also a throughout literature review.

show abstract

“…Pityriasis rubra pilaris (PRP) is a group of uncommon chronic inflammatory skin conditions with unclear pathophysiology and etiology, 1 characterized by palmoplantar keratoderma and varying degrees of erythematous keratotic papules tending to confluence, with islands of uninvolved skin, 'sparing' 2 . There are six subtypes described, known as Griffith's classification 3 .…”

Section: Patient No/sex Age At Onset (Y) Loc* Prp Type Weight (Kg)^ Hosp Topical Agent Physical Therapy Systemic Agent Biologic Agent CLImentioning

confidence: 99%

Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital

Ringin

Baker

Foley

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a group of uncommon chronic inflammatory skin conditions with unclear pathophysiology and etiology. To date there is limited published literature and no clinical guidelines for the management of PRP. Infliximab, alone or in combination, is the most widely published successful treatment for adults and etanercept for pediatric populations. We present a case series of patients diagnosed with PRP. Retrospective data were collected from a tertiary Australian dermatology department between January 2010 and December 2019 on patients with PRP. Electronic medical records and pathology database were searched. A total of 13 patients were included. Twelve of the 13 patients used topical agents and three patients attempted narrow-band ultraviolet B phototherapy. All patients received acitretin as first line systemic agent with the dose varying from 10 to 50 mg daily. Six patients treated with acitretin reported adverse events, requiring dose reduction or cessation.Of the nine patients who did not receive a biologic agent, complete clearance of PRP was achieved in five cases. At least one biologic agent was used in four cases with two experiencing a marked improvement. Overall, complete clearance was achieved in six patients. PRP continues to be a challenge to treat with many treatment options used with variable efficacy.

show abstract

Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl

Cited by 17 publications

References 19 publications

CARD14‐associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature

CARD14‐associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature

Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review

Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital

Contact Info

Product

Resources

About